Back to Search
WILLIAM BENEDICT, M.D.
M.D.
Internal Medicine Physician
NPI: 1902845076Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
R6999(MO)
Research & Publications (20)
Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker.
PMID 19197325·Cancer Gene Ther·2009
8-other
Early RB94-produced cytotoxicity in cancer cells is independent of caspase activation or 50 kb DNA fragmentation.
PMID 18654611·Cancer Gene Ther·2009
8-other
Perioperative and long-term operative outcomes after surgery for trigeminal neuralgia: microvascular decompression vs percutaneous balloon ablation.
PMID 18597696·Head Face Med·2008
4-observational
Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy.
PMID 18458673·Lab Invest·2008
8-other
Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53-induced apoptosis.
PMID 18443131·Neuro Oncol·2008
8-other
Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo.
PMID 18381961·Clin Cancer Res·2008
7-preclinical
Intraventricular schwannoma in a 15-year-old adolescent: a case report.
PMID 18175126·Childs Nerv Syst·2008
5-case
Conditioned medium from Ad-IFN-alpha-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect.
PMID 18617914·Cancer Gene Ther·2008
8-other
Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia.
PMID 17702869·Proc Natl Acad Sci U S A·2007
8-other
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
PMID 17671130·Clin Cancer Res·2007
3-trial
Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer.
PMID 17437845·J Urol·2007
7-preclinical
Carotid artery pseudoaneurysm resulting from an injury to the neck by a fouled baseball.
PMID 17368675·J Neurol Sci·2007
5-case
Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects.
PMID 17096027·Cancer Gene Ther·2007
8-other
Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation.
PMID 16082384·Cancer Gene Ther·2006
4-observational
Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression.
PMID 16469639·J Urol·2006
7-preclinical
Evidence for alternative candidate genes near RB1 involved in clonal expansion of in situ urothelial neoplasia.
PMID 16402033·Lab Invest·2006
8-other
Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells.
PMID 17172406·Mol Cancer Ther·2006
7-preclinical
Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells.
PMID 15604261·Cancer Res·2004
8-other
Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein.
PMID 15336652·Mol Ther·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 226 S WOODS MILL RD, SUITE 56W
CHESTERFIELD, MO 63017 - Phone
- (314) 373-2501
Quick Facts
- NPI
- 1902845076
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile